世界の二重特異性抗体市場(~2026):市場機会・売上・臨床試験インサイト

■ 英語タイトル:Global Bispecific Antibody Market Opportunity, Drug Sales and Clinical Trials Insight 2026

調査会社Kuick Research社が発行したリサーチレポート(データ管理コード:KUIK21FB018)■ 発行会社/調査会社:Kuick Research
■ 商品コード:KUIK21FB018
■ 発行日:2020年2月
■ 調査対象地域:グローバル
■ 産業分野:医療
■ ページ数:510
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール
■ 販売価格オプション(消費税別)
Single userUSD2,400 ⇒換算¥355,200見積依頼/購入/質問フォーム
Multi UserUSD4,800 ⇒換算¥710,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Kuick Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[世界の二重特異性抗体市場(~2026):市場機会・売上・臨床試験インサイト]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

本市場調査レポートでは、世界の二重特異性抗体市場について調査・分析を行い、イントロダクション、二重特異性抗体の開発、作用機序、診断&治療における二重特異性抗体の応用、市場概要、投与量・価格分析、売上分析、臨床パイプライン、市販用二重特異性抗体の臨床洞察、市場動向、今後の展望、競争状況などを掲載しています。
・イントロダクション
・二重特異性抗体の開発
・作用機序
・診断&治療における二重特異性抗体の応用
・市場概要
・投与量・価格分析
・売上分析
・臨床パイプライン
・市販用二重特異性抗体の臨床洞察
・市場動向
・今後の展望
・競争状況

“Global Bispecific Antibody Market Opportunity, Drug Sales and Clinical Trials Insight 2026″ Report Highlights:

Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
Global Bispecific Antibody Pipeline: 333 Drug
Commercially Available Bispecific Antibodies: 2 (Blincyto and Hemlibra)
Hemlibra Sales and Market Share 2019: > US$ 1.4 Billion and > 80%

“Global Bispecific Antibody Market Opportunity, Drug Sales and Clinical Trials Insight 2026” provides comprehensive insight on clinical and non-clinical factors that are driving the global bispecific antibodies market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on two (Blincyto and Hemlibra) commercially available bispecific antibodies with their regional level revenue, market share and the clinical profile.

“Since Commercially Launch In 2015, The Global Bispecific Antibody Market Has Witnessed Growth of 118% CAGR Till 2019″

The availability of the bispecific antibodies in the market and the revenue generated by the drugs in short span of four years (since commercialization in 2015) clearly depicts the current dominant trends followed by its characterization as a next generation of antibody therapy. The number of the investigational agents under preclinical and clinical trials all around the globe adds as a major key component for the establishment of the antibody therapy as a one stop treatment for all the disease.

Pharmaceutical companies involved in the development of these promising bispecific antibodies molecules strongly believe that their products are superior to first generation nonspecific antibody products. No doubt they are adamant to their viewpoint that bispecific antibodies will be more potent against disease targets, which includes combating more than one aspect of the disease simultaneously, better and cheaper production with least side effects. The molecules are also said to have the potential of dealing with multiple disease with a single agent making them more important.

“Structural Diversity Among The Antibodies Are Opening A Wide Plethora For The Novel Bispecific Antibody Agents, And Thus Providing A Great Opportunity For Establishing A Superior Market In The Future.”

Bispecific antibodies are not only being developed for the oncological use but also the non oncological which includes rejection of organ transplants, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, allergies and ophthalmic problems making their usage area wide enough to make ample of monetary gains in the near future. Their vitality if approved can also make them a great tool in the diagnostics tests detect and monitor infectious agents like HIV, the cause of AIDS, or the influenza virus causing pandemic flu and for identifying diseases released by biological weapons such as smallpox and anthrax. In addition, monoclonal antibodies have also helped in checks for salmonella and bacteria that cause food poisoning. The global opportunity value of the bispecific antibody market is estimated to be approximately US$ 10 billion per year, which is expected to be achieved in next five year timeframe.

*** レポート目次(コンテンツ)***

Introduction to Bispecific Monoclonal Antibody

1.1 Overview of Monoclonal Antibody
1.2 Overview of Bispecific Monoclonal Antibody
1.3 Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

The Engineering and Development of Bispecific Antibodies

2.1 Bispecific Antibodies Similar to IgG

2.1.1 Quadroma (Hybrid Hydromas) Approach
2.1.2 “Knobs Into Holes” Approach
2.1.3 CrossMab Approach
2.1.4 Dual-Variable-Domain Immunoglobulin Approach

2.2 Small Bispecific Antibodies

2.2.1 Bispecific Diabodies
2.2.2 Bispecific T-Cell Engager Antibodies (BiTEs)

Mechanism Of Action Of Bispecific Antibody

3.1 Trifunctional Antibody: Catumaxomab (Removabandreg;)
3.2 Blinatumomab

Applications of Bispecific Antibodies in Diagnostic and Treatment

4.1 BsMAb for Diagnosis of Bacterial and Viral Infectious Diseases
4.2 BsMAb for Cancer Diagnostic
4.3 BsAbs Blocking Signaling Pathways
4.4 BsAbs Targeting Tumor Angiogenesis
4.5 Specific Delivery of Effector Compounds to Targets
4.6 Bispecific Antibodies and Gene Therapy

Global Bispecific Antibody Market Outlook

5.1 Current Market Scenario

5.2 Availability of Bispecific Antibodies
5.2.1 Catumaxomab (Removab)
5.2.2 Blinatumomab
5.2.3 Emicizumab
5.2.4 Duligotumab
5.2.5 SAR 156597

Approved Bispecific Antibody Dosage and Price Analysis

6.1 Blincyto
6.2 Hemlibra

Approved Bispecific Antibody Sales Analysis

7.1 Blincyto
7.2 Hemlibra

Global Bispecific Antibodies Clinical Pipeline Overview

8.1 By Phase
8.2 By Country/Region
8.3 By Company
8.4 By Indication
8.5 Orphan Designated Bispecific Antibodies

Global Bispecific Antibodies Clinical Pipeline By Company, Indication and Phase

9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III

Marketed Bispecific Antibodies Clinical Insight

10.1 Blinatumomab – Amgen
10.2 Emicizumab – Chugai Pharmaceutical

Global Bispecific Antibody Market Dynamics

11.1 Favorable Market Parameters
11.2 Commercialization Challenges

Global Bispecific Antibody Market Future Prospects

Competitive Landscape

13.1 Ablynx
13.2 Adimab
13.3 Affimed Therapeutics
13.4 Amgen
13.5 AstraZeneca (MedImmune)
13.6 Chugai Pharmaceutical
13.7 Eli Lilly
13.8 EMD Serono
13.9 Emergent BioSolutions
13.10 Genentech
13.11 Genmab
13.12 Immunomedics
13.13 Jounce Therapeutics
13.14 MacroGenics
13.15 Merus
13.16 Neovii Biotech
13.17 NovImmune SA
13.18 OncoMed Pharmaceuticals
13.19 Pieris
13.20 Regeneron Pharmaceuticals
13.21 Roche
13.22 Sanofi



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(KUIK21FB018 )"世界の二重特異性抗体市場(~2026):市場機会・売上・臨床試験インサイト" (英文:Global Bispecific Antibody Market Opportunity, Drug Sales and Clinical Trials Insight 2026)はKuick Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。